The content on this site is intended for healthcare professionals only
Prof Oliver Ottmann talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about HSCT in Ph-positive ALL and how it is still the most dependable form of therapy.
Prof Ottmann understands that not every patient is suitable for transplant but with advancements in technology we have seen an improved supportive care, an increase in patient age and an improvement in donor matching.
He goes on to say how both he and his 'opponent' in the debate, Prof Robin Foa, agree that you have to individualise each decision based on the case.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients
Analysis of dexamethasone-enhanced pre-medication in motixafortide-induced haematopoietic stem cell mobilisation for MM
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Choosing the right patients for transplant
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM
More effective treatment options required for patients with MM post lenalidomide exposure
